Background/Aims: Low education has been shown to be a risk factor for dementia. However, little is known about the association between educational level and dementia drugs. Methods: We conducted a register-based study in Sweden of 645,973 people aged 75–89 years. Data on age, sex, type of residential area (urban/rural), dispensed drugs and education were analyzed from people aged 75–89 years registered in the Swedish Prescribed Drug Register during July to October 2005. The 3 main outcome measures were dispensed dementia drugs, cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and memantine. Results: Dementia drugs were used by 3% of the study population, cholinesterase inhibitors by almost 3% and memantine by 0.4%. High education was associated with dementia drugs (OR: 1.26; 95% CI: 1.19–1.34 for ≧15 years of education compared with ≤9 years), cholinesterase inhibitors (OR: 1.25; 95% CI: 1.17–1.33 for ≧15 years of education compared with ≤9 years) and, especially, memantine (OR: 1.46; 95% CI: 1.26–1.68 for ≧15 years of education compared with ≤9 years), after adjustment for age, sex, type of residential area and number of dispensed drugs. Conclusion: The results indicate that there may be inequalities in the use of dementia drugs among elderly Swedes. Future research is required to explain why educational level has the opposite relationship to dementia drugs than to dementia diagnosis.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.